Table 1.

Characteristics of patients treated with immune checkpoint inhibitors

	N = 530 (%)
Age, median (IQR), years	68.5 (61.0–74.0)
Sex
Male	350 (66%)
Female	180 (34%)
Malignancy
Non-small cell lung cancer	348 (66%)
Melanoma	98 (18%)
Renal cell cancer	27 (5%)
Head and neck cancer	18 (3%)
Others	39 (7%)
ICI
Anti-CTLA-4 ± anti-PD1	50 (9%)
Anti-PD-1/PD-L1 alone	480 (91%)
PD-L1 expression (> 1%)	170/234 (73%)
Number of ICI infusions
1–2	145 (27%)
3–10	258 (49%)
More than 11	127 (24%)

ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, ICI immune checkpoint inhibitor, IQR interquartile range, T-Bil total bilirubin